Insulet (NASDAQ:PODD) Reaches New 1-Year Low – Here’s What Happened

Insulet Corporation (NASDAQ:PODD)’s stock price hit a new 52-week low during trading on Wednesday . The stock traded as low as $146.20 and last traded at $148.1310, with a volume of 569929 shares trading hands. The stock had previously closed at $158.35.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Evercore dropped their price objective on shares of Insulet from $240.00 to $200.00 in a research note on Thursday, May 7th. Rothschild & Co Redburn reissued a “neutral” rating and issued a $220.00 price objective (down from $380.00) on shares of Insulet in a research note on Friday, April 24th. Citigroup dropped their price objective on shares of Insulet from $230.00 to $175.00 in a research note on Thursday, May 7th. BTIG Research dropped their price objective on shares of Insulet from $320.00 to $260.00 and set a “buy” rating for the company in a research note on Wednesday, May 6th. Finally, Piper Sandler dropped their price objective on shares of Insulet from $360.00 to $210.00 in a research note on Wednesday, May 6th. Nineteen investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $257.09.

Insulet Price Performance

The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81. The firm has a market capitalization of $10.21 billion, a price-to-earnings ratio of 34.29, a PEG ratio of 1.21 and a beta of 1.20. The business’s fifty day simple moving average is $201.84 and its 200 day simple moving average is $257.75.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. The business had revenue of $761.70 million during the quarter, compared to analysts’ expectations of $729.89 million. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The business’s quarterly revenue was up 33.9% on a year-over-year basis. During the same period last year, the company posted $1.02 earnings per share. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, research analysts forecast that Insulet Corporation will post 6.44 EPS for the current year.

Insider Buying and Selling

In related news, Director Michael R. Minogue purchased 2,030 shares of Insulet stock in a transaction on Wednesday, February 25th. The stock was acquired at an average cost of $246.23 per share, for a total transaction of $499,846.90. Following the completion of the acquisition, the director owned 17,483 shares of the company’s stock, valued at $4,304,839.09. This trade represents a 13.14% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.36% of the company’s stock.

Institutional Investors Weigh In On Insulet

Large investors have recently bought and sold shares of the stock. Vanguard Group Inc. grew its holdings in shares of Insulet by 1.0% during the third quarter. Vanguard Group Inc. now owns 8,796,200 shares of the medical instruments supplier’s stock valued at $2,715,651,000 after buying an additional 87,845 shares during the last quarter. State Street Corp grew its holdings in shares of Insulet by 2.1% during the fourth quarter. State Street Corp now owns 3,155,489 shares of the medical instruments supplier’s stock valued at $896,916,000 after buying an additional 65,317 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Insulet by 2.1% during the fourth quarter. Geode Capital Management LLC now owns 2,006,413 shares of the medical instruments supplier’s stock valued at $568,274,000 after buying an additional 41,019 shares during the last quarter. Invesco Ltd. grew its holdings in shares of Insulet by 10.5% during the fourth quarter. Invesco Ltd. now owns 1,480,562 shares of the medical instruments supplier’s stock valued at $420,835,000 after buying an additional 141,167 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its holdings in shares of Insulet by 462.7% during the first quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock valued at $258,088,000 after buying an additional 1,011,369 shares during the last quarter.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.